4.3 Article

Methods comparison for high-resolution transcriptional analysis of archival material on Affymetrix Plus 2.0 and Exon 1.0 microarrays

期刊

BIOTECHNIQUES
卷 47, 期 1, 页码 587-+

出版社

INFORMA HEALTHCARE
DOI: 10.2144/000113169

关键词

archival; FFPE; expression microarray; Exon array; Plus 2.0

资金

  1. Cancer Research UK
  2. The Christie NHS Foundation Trust

向作者/读者索取更多资源

Microarray gene expression profiling of formalin-fixed paraffin-embedded (FFPE) tissues is a new and evolving technique. This report compares transcript detection rates on Affymetrix U133 Plus 2.0 and Human Exon 1.0 ST GeneChips across several RNA extraction and target labeling protocols, using routinely collected archival FFPE samples. All RNA extraction protocols tested (Ambion-Optimum, Ambion-RecoverAll, and Qiagen-RNeasy FFPE) provided extracts suitable for microarray hybridization. Compared with Affymetrix One-Cycle labeled extracts, NuGEN system protocols utilizing oligo(dT) and random hexamer primers, and cDNA target preparations instead of cRNA, achieved percent present rates up to 55% on Plus 2.0 arrays. Based on two paired-sample analyses, at 90% specificity this equalled an average 30 percentage-point increase (from 50% to 80%) in FFPE transcript sensitivity relative to fresh frozen tissues, which we have assumed to have 100% sensitivity and specificity. The high content of Exon arrays, with multiple probe sets per exon, improved FFPE sensitivity to 92% at 96% specificity, corresponding to an absolute increase of similar to 600 genes over Plus 2.0 arrays. While larger series are needed to confirm high correspondence between fresh-frozen and FFPE expression patterns, these data suggest that: both Plus 2.0 and Exon arrays are suitable platforms for FFPE microarray expression analyses.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Cardiac & Cardiovascular Systems

Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity

Peter A. Henriksen, Peter Hall, Olga Oikonomidou, Iain R. MacPherson, Morag Maclean, Steff Lewis, Heather McVicars, Angus Broom, Fiona Scott, Pam McKay, Annabel Borley, Clare Rowntree, Simon Lord, Graham Collins, John Radford, Amy Guppy, John R. Payne, David E. Newby, Nick L. Mills, Ninian N. Lang

Summary: The Cardiac CARE trial aims to investigate the effects of cardiac biomarker monitoring and combination drug therapy on patients receiving anthracycline chemotherapy. By monitoring the impact of beta-adrenergic receptor blockers and renin-angiotensin-system inhibitors on cardiac function, the trial seeks to find a treatment strategy to mitigate the cardiotoxicity of anthracycline drugs.

CIRCULATION-HEART FAILURE (2022)

Article Medicine, General & Internal

Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma

Stephen M. Ansell, John Radford, Joseph M. Connors, Monika Dlugosz-Danecka, Won-Seog Kim, Andrea Gallamini, Radhakrishnan Ramchandren, Jonathan W. Friedberg, Ranjana Advani, Martin Hutchings, Andrew M. Evens, Piotr Smolewski, Kerry J. Savage, Nancy L. Bartlett, Hyeon-Seok Eom, Jeremy S. Abramson, Cassie Dong, Frank Campana, Keenan Fenton, Markus Puhlmann, David J. Straus

Summary: The study found that using A+AVD for the treatment of stage III or IV Hodgkin's lymphoma provides a survival advantage over ABVD.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Review Hematology

Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study

Georg Hess, Martin Dreyling, Lucie Oberic, Eva Gine, Pier Luigi Zinzani, Kim Linton, Adam Vilmar, Mats Jerkeman, Jenny M. H. Chen, Anke Ohler, Stephan Stilgenbauer, Catherine Thieblemont, Jonathan Lambert, Vittorio Ruggero Zilioli, Juan-Manuel Sancho, Ana Jimenez Ubieto, Luca Fischer, Toby A. Eyre, Sam Keeping, Julie E. Park, James J. Wu, Rubina Siddiqi, John Reitan, Sally Wade, Gilles Salles

Summary: Relapsed Mantle cell lymphoma (MCL) has a poor prognosis and there is no standard treatment. This study examined the outcomes of salvage therapy in MCL patients who failed Bruton tyrosine kinase inhibitor (BTKi) therapy, showing shorter overall survival in this group compared to those who received post-BTKi therapy.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Article Hematology

Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study

Paola Ghione, Maria Lia Palomba, Herve Ghesquieres, Sabela Bobillo, Anik R. Patel, Myrna Nahas, Steve Kanters, Kevin Deighton, Anthony Hatswell, Long Ma, Eve H. Limbrick- Oldfield, Julia Thornton Snider, Sally W. Wade, Maria Teresa Riberio, John Radford, Sara Beygi, John Gribben

Summary: The SCHOLAR-5 study examines the treatment patterns and outcomes of real-world follicular lymphoma (FL) patients who are in the 3rd line of treatment or higher, where existing data are limited. The study found that the most common regimen in each line of treatment was chemoimmunotherapy, but experimental drugs were increasingly used at later lines of treatment. The overall response rate decreased with each line of treatment, and the duration of response and survival diminished with each subsequent line.

HAEMATOLOGICA (2023)

Article Hematology

Management of secondary central nervous system lymphoma

Kate Cwynarski, Thomas Cummin, Wendy Osborne, Joanne Lewis, Sridhar Chaganti, Jeff Smith, Kim Linton, Paul Greaves, Pam McKay, Christopher P. Fox

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Article Oncology

A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma

M. Lia Palomba, Paola Ghione, Anik R. Patel, Myrna Nahas, Sara Beygi, Anthony J. Hatswell, Steve Kanters, Eve H. Limbrick-Oldfield, Sally W. Wade, Markqayne D. Ray, Jessica Owen, Sattva S. Neelapu, John Gribben, John Radford, Sabela Bobillo

Summary: In the ZUMA-5 trial, axicabtagene ciloleucel (axi-cel) showed high rates of durable response in relapsed/refractory follicular lymphoma (FL) patients and clear superiority compared to the SCHOLAR-5 external control cohort. This study provides an updated analysis using 24-month data from ZUMA-5.

EXPERT REVIEW OF ANTICANCER THERAPY (2023)

Article Archaeology

Enhancing mummy ?palaeobiographies? through the use of multidisciplinary techniques and approaches

K. N. White, D. Chiasserini, R. Loynes, A. R. David, B. E. van Dongen, K. Drosou, R. Forshaw, S. Fraser, P. Causey-Freeman, J. Metcalfe, E. Murphy, M. Regan, P. J. Reimer, D. G. Tosh, A. Whetton, A. J. Freemont

Summary: Scientific examination of mummies provides insights into human ancestry, diet, disease, cultures, and societies. However, invasive methods have raised concerns. A minimally invasive approach using imaging techniques and biopsy sampling allows for the collection of valuable data without significant disturbance to the mummy. This study on Takabuti demonstrates the potential of such methods.

JOURNAL OF ARCHAEOLOGICAL SCIENCE-REPORTS (2023)

Article Medicine, General & Internal

The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 study

Radhakrishnan Ramchandren, Peter Johnson, Nilanjan Ghosh, Jia Ruan, Kirit M. Ardeshna, Roderick Johnson, Gregor Verhoef, David Cunningham, Sven de Vos, Shireen Kassam, Luis Fayad, John Radford, Sarah Bailly, Fritz Offner, David Morgan, Javier Munoz, Jerry Ping, Edith Szafer-Glusman, Karl Eckert, Jutta K. Neuenburg, Andre Goy

Summary: This study evaluated the efficacy and safety of the combination of ibrutinib, lenalidomide, and rituximab in patients with relapsed/refractory DLBCL ineligible for stem cell transplantation. The results showed that the combination therapy demonstrated durable antitumor activity in DLBCL patients.

ECLINICALMEDICINE (2023)

Article Hematology

Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma

Philippe Armand, Pier Luigi Zinzani, Hun Ju Lee, Nathalie A. Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A. Shipp, Alex F. Herrera, Jianxin Lin, Eunhee Kim, Samhita Chakraborty, Patricia Marinello, Craig H. Moskowitz

Summary: This study demonstrates that Pembrolizumab provides durable antitumor activity in patients with relapsed or refractory classical Hodgkin lymphoma, and a second course of treatment can reinduce sustained responses after relapse from initial complete response.
Article Oncology

Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma

Hoa Van Le, Kim Van Naarden Braun, Grzegorz S. Nowakowski, David Sermer, John Radford, William Townsend, Herve Ghesquieres, Tobias Menne, Edit Porpaczy, Christopher P. Fox, Claudia Schusterbauer, Fei Fei Liu, Lihua Yue, Marc De Benedetti, Jens Hasskarl

Summary: This study compared the efficacy of lisocabtagene maraleucel (liso-cel) with conventional therapies in relapsed/refractory large B-cell lymphoma patients. The study used a real-world population as the comparator and matched patients' characteristics with those in a clinical trial. Results showed that liso-cel had significantly better overall response rate, complete response rate, overall survival, and progression-free survival compared to conventional therapies.

LEUKEMIA & LYMPHOMA (2023)

Article Multidisciplinary Sciences

Interobserver variability in interim PET assessment in Hodgkin lymphoma-reasons and solutions

Thomas S. Georgi, Lars Kurch, Dirk Hasenclever, Victoria Warbey, Lucy Pike, John F. Radford, Osama Sabri, Regine Kluge, Sally Barrington

Summary: The aim of this study was to evaluate the causes of interobserver variability in assigning the Deauville score (DS) for interim PET (iPET) scans in Hodgkin lymphoma (HL) patients and propose suggestions for improvement. The results showed that a concordant visual DS result was achieved in 56% of the iPET scans, with a minor discrepancy of one DS level in 33% and a major discrepancy of more than one DS level in 11%. The main reasons for major discrepancies were different interpretation of PET-positive lymph nodes, missed lesions, and different assessment of lesions in activated brown fat tissue. In 51% of minor discrepancy scans with residual lymphoma uptake, additional quantification resulted in a concordant quantitative DS result.

PLOS ONE (2023)

Article Hematology

The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network

Greg Hapgood, Monica Civallero, Yana Stepanishyna, Julie Vose, Monica Elena Cabrera, Ranjana H. Advani, Stefano A. Pileri, Martina Manni, Steven M. Horwitz, Francine M. Foss, Felicitas Hitz, John Radford, Ivan Dlouhy, Carlos Chiattone, Won Seog Kim, Tetiana Skrypets, Arnon Nagler, Judith Trotman, Stefano Luminari, Int T Cell Project

Summary: This study investigated the natural history and prognostic factors of limited-stage peripheral T-cell lymphomas (PTCLs) and developed a predictive model for overall survival (OS), which showed good discriminatory power and was validated in an independent cohort.

BLOOD ADVANCES (2023)

Proceedings Paper Computer Science, Artificial Intelligence

LIMITATIONS OF AUTOMATED SEGMENTATION TOOLS FOR BREAST TISSUE IN YOUNG WOMEN TREATED WITH RADIOTHERAPY TO THE CHEST

H. Chamberlin, E. Henderson, R. Cowan, C. Anandadas, C. Hague, F. Wilson, J. Radford, S. Howell, S. Astley, M. Aznar, E. Vasquez Osorio

Summary: The performance of commercially available segmentation tools (deep learning and atlas-based) was evaluated for breast contouring in young lymphoma patients. Deep learning segmentation performed better in most patients, while atlas-based segmentation was best in a few patients. Variation in breast densities and arm positions may affect auto-contouring performance.

2023 IEEE 20TH INTERNATIONAL SYMPOSIUM ON BIOMEDICAL IMAGING, ISBI (2023)

Meeting Abstract Oncology

Primary Efficacy and Safety Analysis of a Global Phase II Study of Zandelisib Administered by Intermittent Dosing (ID) in Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL): The TIDAL Study

Tycel Phillips, Wojciech Jurczak, Vincent Ribrag, Kim Linton, Graham P. Collin, Javier Lopez-Jimenez, Nishitha Reddy, Andrea Mengarelli, Gerardo Musuraca, Oonagh Sheehy, Weiming Xu, Michel Azoulay, Richard G. Ghalie, Pier Luigi Zinzani, Andrew D. Zelenetz

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)

Meeting Abstract Oncology

First-Line Treatment With Subcutaneous Epcoritamab plus R-CHOP in Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL): Phase 1/2 Data Update

Lorenzo Falchi, Fritz Offner, David Belada, Joshua Brody, Kim M. Linton, Yasmin Karimi, Raul Cordoba, Sylvia Snauwaert, Aqeel Abbas, Liwei Wang, Jun Wu, Brian Elliott, Michael Roost Clausen

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)

暂无数据